
|Videos|December 10, 2011
Dr. Kochenderfer Discusses the B-cell Antigen CD19
Author(s)James N. Kochenderfer, MD
Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19
Advertisement
James N. Kochenderfer, MD, Experimental Transplantation and Immunology Branch, National Cancer Institute in Bethesda, MD, discusses the B-cell antigen CD19 and its role in chemotherapy-resistant B-cell malignancies. At the 53rd Annual Meeting of the American Society of Hematology, held at the San Diego Convention Center, Kochenderfer presented data on 8 patients treated with an anti-CD19 chimeric antigen receptor. While the agent did cause some toxicity in patients, it was able to eliminate targeted cells.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
5






































































